The Genitourinary Oncology Program consists of a group of basic and clinical investigators collectively focused upon the study and treatment of genitourinary malignancies. The goals of the program include optimal multidisciplinary care through interaction of clinicians of various disciplines, understanding disease biology through the study of basic mechanisms of carcinogenesis and tumor progression, advancement of clinical care through effective implementation of clinical trials, and development of novel preventive and therapeutic strategies through collaboration of basic investigators and clinicians. The program facilitates the achievement of its goals through inter-programmatic seminars and conferences, provision of access to cancer center core facilities and program resources, and acting to identify additional opportunities to maximize the success of collaborations and individual program members. Historically, the main clinical focus of the NYU GU Oncology program has been prostate cancer due to the Department of Urology's longstanding clinical focus in the disease, the large volume of patients, and the number of basic investigators focused in the disease. This remains the most well-developed focus of the program. In the area of bladder cancer, the NYU program has a strong basic research group focused in urothelial biology and urothelial carcinogenesis. While there are ongoing clinical trials in bladder cancer, the program continues to seek additional physician scientists focused in the area of translational and clinical research in bladder cancer. At present, there are 27 program members with appointments in 12 departments within the medical school. 15/27 members are primarily focused in the area of prostate cancer, while 6/27 are focused in trie study of urothelial cancer. The group consists of 9 clinician scientists, 13 basic investigators, and one statistician. Total NCI funding has increased from $1,377,698 to $1,708,288. Membership has increased from 24 to 27. Total publications over the past five years total 211 of which 18% are intra-programmatic and 10% are interprogrammatic.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
New York
United States
Zip Code
Huang, Chao; Zeng, Xingruo; Jiang, Guosong et al. (2017) XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell. J Hematol Oncol 10:6
Silvera, Deborah; Ernlund, Amanda; Arju, Rezina et al. (2017) mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells. Mol Cell Biol 37:
Koh, Hyunwook; Blaser, Martin J; Li, Huilin (2017) A powerful microbiome-based association test and a microbial taxa discovery framework for comprehensive association mapping. Microbiome 5:45
Ma, Lijie; Liu, Yan; Landry, Nichole K et al. (2017) Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. PLoS One 12:e0186769
Morabito, Michael V; Ravussin, Yann; Mueller, Bridget R et al. (2017) Weight Perturbation Alters Leptin Signal Transduction in a Region-Specific Manner throughout the Brain. PLoS One 12:e0168226
Koetz-Ploch, Lisa; Hanniford, Douglas; Dolgalev, Igor et al. (2017) MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res 30:328-338
Feig, Jessica L; Mediero, Aranzazu; Corciulo, Carmen et al. (2017) The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin. PLoS One 12:e0188135
Ono, Kentaro; Viet, Chi T; Ye, Yi et al. (2017) Cutaneous pigmentation modulates skin sensitivity via tyrosinase-dependent dopaminergic signalling. Sci Rep 7:9181
Wang, Xing; Zhang, Fenglin; Wu, Xue-Ru (2017) Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. Sci Rep 7:45983
Garré, Juan Mauricio; Silva, Hernandez Moura; Lafaille, Juan J et al. (2017) CX3CR1+ monocytes modulate learning and learning-dependent dendritic spine remodeling via TNF-?. Nat Med 23:714-722

Showing the most recent 10 out of 1082 publications